Cipher Pharmaceuticals appoints Robert D. Tessarolo as CEO
Mr. Tessarolo will also be nominated for election as a director at the Company's next annual general meeting in May 2017.
Mr. Tessarolo has 22 years of experience in the pharmaceutical industry.
He most recently held the position of Vice President & General Manager with Celgene Corporation, where he was responsible for leading their U.S. Inflammation & Immunology business.
Prior to Celgene, Mr. Tessarolo led the launch of Actavis, plc's Canadian Specialty Pharmaceutical Division and served as President and General Manager.
He established a Canadian business, leading his team through several new product launches and the successful integration of multiple company acquisitions, including Warner Chilcott, Forest Labs and Allergan.
Prior to joining Actavis, Mr. Tessarolo held a number of positions of increasing responsibility with Biovail Pharmaceuticals Canada, culminating in his appointment to the position of Vice President and General Manager.
He serves on the Board of Directors of Bradmer Pharmaceuticals.
Mr. Tessarolo is a graduate of Carleton University with a B.A. in Economics and has attended the Advanced Management Program for General Management at Ross School of Business at the University of Michigan. ■
LATEST MOVES FROM Ontario
- Canada Goose appoints John Davison to board
- Sphere 3D appoints Cheemin Bo-Linn to board
- Ascendant Resources appoints Mark Brennan as executive chairman
- Titan Medical appoints Curtis R. Jensen as vice president
- Manulife promotes Roy Gori to president
More inside POST
How board political ideology affects CEO pay Leadership